Document is current
Any future updates will be listed below
-
Authors
Feriel, Benchenouf
Alessandra, Cuomo
Deborah, Gorth J.
Corinne, Normand
Raphaël, Thuillet
Mina, Ottaviani
Ali, Akamkam
Jean-Baptiste, Menager
Guillaume, Fadel
Julien, Grynblat
Maria-Rosa, Ghigna
Elie, Fadel
Laurent, Savale
Olaf, Mercier
Ly, Tu
Marc, Humbert
Christophe, Guignabert https://orcid.org/0000-0002-8545-4452
- License Information
-
More Information
Article History
Received: 20 June 2024
Accepted: 10 November 2024
First Online: 16 November 2024
Declarations
:
: Over the last three years, C.G. reports grants from Acceleron Pharma (Cambridge, MA, USA), a wholly-owned subsidiary of Merck & Co., Inc. (Rahway, NJ, USA), MSD, Corteria, Structure therapeutics, Diagonal Therapeutics, Gossamer, outside the submitted work. M.H. reports grants and personal fees from Acceleron, Aerovate, Altavant, AOP Orphan, Bayer, Chiesi, Ferrer, Janssen, Merck, MorphogenIX and United Therapeutics, outside the submitted work. All the other authors declare that there is no conflict of interest regarding the publication of this original article.
